<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97261">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01658657</url>
  </required_header>
  <id_info>
    <org_study_id>12-1133</org_study_id>
    <nct_id>NCT01658657</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension</brief_title>
  <official_title>A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of plasma renin activity-guided
      therapy for determining hypertension treatment. Plasma renin is an enzyme in your blood that
      can be measured to determine your hypertension subtype. Once the subtype is known, doctors
      can prescribe specific medications to target your specific hypertension subtype. This study
      will investigate whether targeting the specific hypertension subtype helps to achieve blood
      pressure control sooner and with fewer medications compared to a standard fixed dose
      combination therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Blood pressure control, as defined as office BP measurement of &lt;140 mmHg systolic and &lt;90 mmHg diastolic</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At each study visit (approximately every 30 days), participants' BP will be checked.  If BP is controlled (&lt;140mmHG systolic and &lt;90mmHG diastolic), then current medication will continue.  If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hypertension</condition>
  <condition>Plasma Renin Activity</condition>
  <arm_group>
    <arm_group_label>PRA-guided therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed-dose combination treatment-guided therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <arm_group_label>PRA-guided therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <arm_group_label>PRA-guided therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <arm_group_label>PRA-guided therapy</arm_group_label>
    <arm_group_label>Fixed-dose combination treatment-guided therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol</intervention_name>
    <arm_group_label>PRA-guided therapy</arm_group_label>
    <arm_group_label>Fixed-dose combination treatment-guided therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisinopril/hydrochlorothiazide</intervention_name>
    <arm_group_label>Fixed-dose combination treatment-guided therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systolic BP average during at least one recent (within 1 month) clinic or emergency
             room  visit ≥ 150 mmHg, or diastolic BP average  during at least one recent (within 1
             month) clinic or emergency room  visit ≥ 95 mmHg

          -  Not currently taking BP-lowering medication

          -  Clinician recommends pharmacologic treatment

          -  Willing to make necessary study visits

          -  Able to be contacted by phone

          -  Has a primary care clinician

          -  At least 18 years old

        Exclusion Criteria:

          -  Known secondary cause of hypertension

          -  Pregnancy

          -  Known diabetes, coronary artery disease or renal disease

          -  Known sulfonamide allergy  or history of gout

          -  Participant's clinician recommends he/she not enroll

          -  Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia  at baseline visit

          -  Baseline visit systolic visit BP average &lt; 140 mmHg and diastolic BP average &lt; 90 mm
             Hg

          -  Resting heart rate &lt; 55 beats per minute
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Viera, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Distinguished Associate Professor, Family Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>July 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Anthony J Viera, MD, MPH</investigator_full_name>
    <investigator_title>Distinguished Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
